William M. Feinberg Lecture: Stroke therapy in the year 2025-Burden, breakthroughs, and barriers to progress

被引:61
作者
Broderick, JP [1 ]
机构
[1] Univ Cincinnati, Coll Med, Div Neurol, Cincinnati, OH 45242 USA
关键词
genetics; incidence; risk factors; stroke; acute; stroke prevention;
D O I
10.1161/01.STR.0000106160.34316.19
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background-More than 700000 strokes occurred in the United States during 2002, of which approximately 500 000 are first-ever strokes and 200000 recurrent strokes. If we would decrease the enormous burden of stroke throughout the world, we first need to know the barriers that we have to overcome. These are quite similar to the barriers that we have tried to surmount during the last 25 years. Stroke Prevention-We have developed many successful primary and secondary therapies to prevent stroke over the past 25 years and have begun to understand some of the genetic risk factors underlying stroke. Yet, the incidence rate of stroke in Rochester, Minn, remained unchanged from 1975 to the mid-1990s, and mortality rates for Ohio have changed little for men, women, blacks, and whites over the past decade. The primary reason that we have made little progress in decreasing the burden of stroke is that we have made little progress in modifying the primary risk factors for stroke in the population. Other barriers of improved stroke prevention in the future include costs of therapy and aging of blood vessels and brain, which is the most important risk factor for stroke. Acute Stroke-Breakthroughs in acute stroke treatment are likely to follow the steps of cardiology with the primary focus for ischemic stroke on the restoration of oxygenated blood flow to ischemic brain as quickly as possible. To improve acute stroke therapy in the year 2025, we need to have more focused messages sent to the lay public about stroke warning signs, better and safer methods to open arteries quickly, truly effective neuroprotection in the setting of reperfusion, regional organization for acute stroke therapy, and large randomized trials to find clinically important but smaller benefits. A scientifically proven treatment for treatment of acute intracerebral hemorrhage is another major goal. Recovery After Stroke-Brain recovery after stroke is the area of scientific discovery with the largest potential for advances far into the next century. Obstacles that block effective therapies in the recovery from stroke include the extent of initial injury from stroke, the brain plasticity of a given patient, and, most importantly, understanding the "neural code"-how the brain is organized and how cells communicate with one another.
引用
收藏
页码:205 / 211
页数:7
相关论文
共 74 条
[1]  
Adams RJ., 1998, NEW ENGL J MED, V339, P5, DOI [10.1056/NEJM199807023390102, DOI 10.1056/NEJM199807023390102]
[2]   Antithrombotic and thrombolytic therapy for ischemic stroke [J].
Albers, GW ;
Easton, JD ;
Sacco, RL ;
Teal, P .
CHEST, 1998, 114 (05) :683S-698S
[3]   Ultrasound-enhanced thrombolysis for stroke: Clinical significance [J].
Alexandrov, Andrei V. .
European Journal of Ultrasound, 2002, 16 (1-2) :131-140
[4]  
[Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P409
[5]  
[Anonymous], 1978, N ENGL J MED
[6]  
[Anonymous], 1982, JAMA-J AM MED ASSOC, V247, P633
[7]   Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: A metaanalysis [J].
Barker, FG ;
Ogilvy, CS .
JOURNAL OF NEUROSURGERY, 1996, 84 (03) :405-414
[8]   Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis [J].
Barnett, HJM ;
Taylor, W ;
Eliasziw, M ;
Fox, AJ ;
Ferguson, GG ;
Haynes, RB ;
Rankin, RN ;
Clagett, GP ;
Hachinski, VC ;
Sackett, DL ;
Thorpe, KE ;
Meldrum, HE ;
Spence, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (20) :1415-1425
[9]   Agalsidase alfa - a preparation for enzyme replacement therapy in Anderson-Fabry disease [J].
Beck, M .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) :851-858
[10]  
Bergeron P, 1999, J ENDOVASC SURG, V6, P155, DOI 10.1583/1074-6218(1999)006<0155:PSOTIC>2.0.CO